Predictive Technology Group, Inc. Announces Executive Changes
February 17, 2021 at 04:24 pm EST
Share
On February 17, 2021, Simon Brewer tendered his resignation as Chief Financial Officer of Predictive Technology Group, Inc. and its subsidiaries (the ‘Company’). Such resignation is effective immediately. Mr. Brewer will assist the Company in the transition of the Chief Financial Officer role and continue on in a consulting capacity. Mr. Brewer's departure is not due to a dispute or disagreement with the Company. Mr. Brewer has accepted the role of Chief Financial Officer for Operation Underground Railroad, a non-profit organization dedicated to fighting human trafficking worldwide. In connection with Mr. Brewer's resignation, the Company will initiate a search for a replacement CFO. In the interim, the Board of Directors has appointed Jacob Easdale as Interim CFO of Predictive Technology Group, Inc. and its subsidiaries effective February 17, 2021. Mr. Easdale, a Certified Public Accountant, has over 15 years' experience in finance and accounting spending the majority of that time working with public companies. Prior to his work in the private sector, Mr. Easdale was an auditor for KPMG LLP.
Predictive Technology Group, Inc. is a life science company. The Company, through its subsidiaries, is focused on specific points of the care continuum, including detection, prevention and treatment. Predictive Analytics, Predictive Laboratories, and Predictive Biotech each bring critical solutions to personalized patient care by leveraging its research, genomics, genetic library and expertise in developing bioscience solutions. Predictive Analytics is the repository for its genetic library. Predictive Biotech provides regenerative medicine. Its products are derived from tissue sources rich in properties that support the bodyâs natural ability to heal itself. All products are safely, ethically and minimally processed to deliver allografts that preserve the naturally occurring characteristics and factors of the donor tissue. Its research and use of processing methods has propelled its placental-derived and Whartonâs Jelly umbilical cord-derived products to new heights.